Radioligand Therapy Side Effects and How to Manage Them


Common Side Effects

Radioligand therapy for prostate cancer is also called PSMA therapy because it targets prostate-specific membrane antigen (PSMA), a type of protein found in large amounts on the surface of up to 90 percent of prostate cancer cells.

But PSMA is also found in smaller quantities on various other tissues in the body, such as the small intestines, liver, kidneys, and salivary glands.

Most of the side effects from the treatment occur because the medication, lutetium Lu-177 vipivotide tetraxetan (Pluvicto), has attached to and damaged these normal tissues.

“Generally, this is a very well-tolerated treatment with limited side effects in most patients,” says Amir Iravani, MD, a nuclear medicine physician with UCLA in Los Angeles.



Source link

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top